In pharma tax probe, Wyden ⁠puts Pfizer in hot seat with CEO letter

Three years into a Senate Finance Committee investigation into Big Pharma’s tax strategies, committee Chair Ron Wyden, D-Oregon, has set his sights on Pfizer.

By sending a letter to Pfizer CEO Albert Bourla, Ph.D., Wyden hopes to learn more about the tax payments made by the pharma giant in recent years. The senator noted that the company's 9.6% tax rate in 2022—and its negative tax rate last year—were “substantially lower” than the U.S. corporate tax rate of 21%.